The LuViva® Advanced Cervical Scan continues to demonstrate the capability to screen the general population for cervical cancer and to eliminate unnecessary testing for women who are screened by other methods, according to recent studies presented at the 25th Turkish...
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced the pricing of a public offering and the entry into definitive agreements with purchasers for the sale of approximately 16.8 million shares of its common stock, and warrants to purchase shares of...
Results of two clinical studies of the LuViva® Advanced Cervical Scan showed the versatility of the technology in its ability to screen the general population for cervical cancer and to eliminate unnecessary testing for women who are screened by other methods. The...
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced its operating results for the third quarter and nine months ended September 30, 2014. Revenue and other income for the third quarter ended September 30, 2014 was approximately $284,000, including...
Guided Therapeutics, Inc. (OTCQB: GTHP), developer of a rapid and painless testing platform that uses biophotonics for the early detection of disease, today announced that it is scheduled to report financial results for its third quarter ended September 30, 2014 on...
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that its Turkish distributor, ITEM Medical Technologies Group, referred to as ITEM, has committed to invest $200,000 in a private placement of Guided Therapeutics’ common stock. Pursuant to the...
